Journal article
Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates
Abstract
A variety of plasma-derived (pd) and recombinant (r) factor VIII (FVIII) concentrates are used to prevent and treat bleeding in severe hemophilia A patients. A significant side effect of FVIII replacement is the development of FVIII neutralizing antibodies (inhibitors) in up to 30% of patients receiving FVIII concentrates. The FVIII protein content (FVIII:Ag) per unit of FVIII:C in FVIII concentrates, and how effectively the FVIII:Ag in FVIII …
Authors
Lin Y; Yang X; Chevrier M; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Journal
Haemophilia, Vol. 10, No. 5, pp. 459–469
Publisher
Wiley
Publication Date
September 2004
DOI
10.1111/j.1365-2516.2004.00957.x
ISSN
1351-8216